Clinical, metabolic, immunologic and genotypic characteristics in non-pediatric patients with type 1A diabetes mellitus. Onset and short-term prognosis;Características clínicas metabólicas, inmunológicas y genotípicas de un grupo de adolescentes y adultos con diabetes millitus tipo 1A. Inicio y pronóstico a corto plazo

Medicina Clinica

Volumn 120, Issue 4, 2003, Pages 121-124

  Aguilera, Eva ^a   Recasens, Mónica ^a   Morŕinigo, Rosa A ^a   Casamitjana, Roser ^a   Oriola, Josep ^a   Ercilla, Guadalupe ^a   Conget, Ignacio ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Autoimmune diabetes; Genetics; Insulin secretion

Indexed keywords

AUTOANTIBODY; GENOMIC DNA; GLUCAGON; GLUTAMATE DECARBOXYLASE ANTIBODY; HLA ANTIGEN CLASS 2; HLA DQ ANTIGEN; HLA DR ANTIGEN; INSULIN; INSULIN ANTIBODY; NUCLEAR FACTOR I; PHOSPHOTYROSINE;

ADOLESCENT; ADULT; AGE; ANTIBODY DETECTION; ARTICLE; AUTOIMMUNITY; CELL FUNCTION; CLINICAL FEATURE; CLINICAL OBSERVATION; CONTROLLED STUDY; DISEASE MARKER; EXON; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HEALTH PROGRAM; HUMAN; IMMUNOLOGICAL PARAMETERS; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; PANCREAS; PANCREAS ISLET BETA CELL; PATHOGENESIS; POPULATION RESEARCH; PROGNOSIS;

EID: 0344838659     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13043011     Document Type: Article

References (26)

1. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-97.
2. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53.
3. Goday A, Castell C, Tresserras R, Canela J, Taberner JL, Lloveras G. Incidence of type 1 (insulin-dependent) diabetes mellitus in Catalonia, Spain. The Catalan Epidemiology Diabetes Study Group. Diabetologia 1992;35:267-71.
4. Onkamo P, Vaananen S, Karvonen M, Tuomilehto J. Worldwide increase in incidence of type I diabetes -the analysis of the data on published incidence trends. Diabetologia 1999;42:1395-403.
5. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001;358:221-9.
6. Moller AM, Dalgaard LT, Pociot F, Nerup J, Hansen T, Pedersen O. Mutations in the hepatocyte nuclear factor-1alpha gene in Caucasian families originally classified as having type I diabetes. Diabetologia 1998;41:1528-31.
7. Montanya E, Fernández-Castaner M, Soler J. Improved metabolic control preserved beta-cell function two years after diagnosis of insulin-dependent diabetes mellitus. Diabetes Metab 1997;23:314-9.
8. Shaa SC, Malone JI, Simpson EN. A randomized trial on intensive insulin therapy in newly diagnosed insulin-dependent diabetes mellitus. N Engl J Med 1989;320:550-4.
9. Madsbad S, Krarup T, Regeur L, Faber OK, Binder C. Effects of strict blood glucose control on residual beta-cell function in insulin dependent diabetics. Diabetologia 1981;20:530-4.
10. Kolb H, Gale EA. Does partial preservation of residual beta-cell function justify immune intervention in recent onset type I diabetes? Diabetologia 2001;44:1349-53.
11. The DCCT Research Group. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). J Clin Endocrinol Metab 1987;65:30-6.
12. Vidal J, Fernández Balsells M, Sesmilo G, Aguilera E, Casamitjana R, Gomis R, et al. Effects of nicotinamide and intravenous insulin therapy in newly diagnosed type 1 diabetes. Diabetes Care 2000;23:360-4.
13. Decochez K, Tits J, Coolens JL, Van Gaal L, Krzentowski G, Winnock F, et al. High frequency of persisting or increasing islet-specific autoantibody levels after diagnosis of type 1 diabetes presenting before 40 years of age. The Belgian Diabetes Registry. Diabetes Care 2000;23:838-44.
14. Torn C, Landin-Olsson M, Lernmark A, Palmer JP, Arnqvist HJ, Blohme G, et al. Prognostic factors for the course of beta cell function in autoimmune diabetes. J Clin Endocrinol Metab 2000;85:4619-23.
15. Savola K, Bonifacio E, Sabbah E, Kulmala P, Vahasalo P, Karjalainen J, et al. IA-2 antibodies-a sensitive marker of IDDM with clinical onset in childhood and adolescence. Childhood Diabetes in Finland Study Group. Diabetologia 1998;41: 424-9.
16. Bilbao JR, Rica I, Vázquez JA, Busturia MA, Castaño L. Influence of sex and age at onset on autoantibodies against insulin, GAD65 and IA2 in recent onset type 1 diabetic patients. Horm Res 2000;54:181-5.
17. Kordonouri O, Hartmann R, Gruters-Kieslich A, Knip M, Danne T. Age-specific levels of diabetes-related GAD and IA-2 antibodies in healthy children and adults. J Pediatr Endocrinol Metab 2002;15:47-52.
18. Escribano-de-Diego J, Sánchez-Velasco P, Luzuriaga C, Ocejo-Vinyals JG, Paz-Miguel JE, Leyva-Cobian F. HLA class II immunogenetics and incidence of insulin-dependent diabetes mellitus in the population of Cantabria (Northern Spain). Hum Immunol 1999;60:990-1000.
19. Gutiérrez-López MD, Bertera S, Chantres MT, Vavassori C, Dorman JS, Trucco M, et al. Susceptibility to type 1 (insulin-dependent) diabetes mellitus in Spanish patients correlates quantitatively with expression of HLA-DQ alpha Arg 52 and HLA-DQ beta non-Asp 57 alleles. Diabetologia 1992;35:583-8.
20. Kawasaki E, Sera Y, Yamakawa K, Abe T, Ozaki M, Uotani S, et al. Identification and functional analysis of mutations in the hepatocyte nuclear factor-1alpha gene in anti-islet autoantibody-negative Japanese patients with type 1 diabetes. J Clin Endocrinol Metab 2000;85:331-5.
21. Costa A, Bescos M, Velho G, Chevre J, Vidal J, Sesmilo G, et al. Genetic and clinical characterisation of maturity-onset diabetes of the young in Spanish families. Eur J Endocrinol 2000;142: 380-6.
22. Fernández Castañer M, Gonzálbez J, Carrera MJ, Nacher V, Montanya E, Abós R, et al. Influencia de la presentación clinica y del control metabólico de la diabetes insulinodependiente en la evolución de la secreción residual de insulina. Estudio prospectivo a cinco años. Med Clin (Barc) 1997;109:328-32.
23. Fernández CM, Montana E, Camps I, Biarnes J, Merino JF, Escriba JM, et al. Ketoacidosis at diagnosis is predictive of lower residual beta-cell function and poor metabolic control in type 1 diabetes. Diabetes Metab 1996;22:349-55.
24. Fernández CM, Pérez M, Maravall J, Montana E, Soler J. Lack of relationship between insulin antibodies, metabolic control and insulin requirements in type 1 diabetes. Diabet Med 1996;13: 686-7.
25. Fernández-Castaner M, Molina A, López-Jiménez L, Gómez JM, Soler J. Clinical presentation and early course of type 1 diabetes in patients with and without thyroid autoimmunity. Diabetes Care 1999;22:377-81.
26. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002;346:1692-8.